Alentis has completed an oversubscribed Series D round. The round was led by Orbimed and co-led by Novo Holdings and Jeito Capital, with contributions from Frazier Life Sciences, Longitude Capital, Catalio Capital, Piper Heartland Healthcare Capital and Avego Bioscience Capital.

The funds will be used to support the clinical development of Alentis’ pipeline of drugs targeted at solid tumours.

More details on the Alentis website.

Next >